Nilotinib and Imatinib Utilization in Iran over 14 years
نویسندگان
چکیده
منابع مشابه
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
BACKGROUND Resistance to imatinib mesylate can occur in chronic myelogenous leukemia (CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL tyrosine kinase inhibitor, is more potent than imatinib against CML cells by a factor of 20 to 50. METHODS In a phase 1 dose-escalation study, we assigned 119 patients with imatinib-resistant CML or acute lymphoblastic leuke...
متن کاملRubella immunisation for girls over 14 years.
Rubella vaccination was offered to a cohort of schoolgirls 14 years and over whose immune state was unknown. This increased the percentage vaccinated or known to be immune from 86% to 90%. It is recommended that rubella vaccination should be offered to girls until they leave school at 16 years of age.
متن کاملPatterns and progress in ovarian cancer over 14 years.
OBJECTIVE To estimate the change in survival rates of women with ovarian cancer during the past 14 years. METHODS Women diagnosed with epithelial, germ cell, sarcomas, and sex-cord stromal ovarian tumors were identified from the Surveillance Epidemiology and End Results Database. Demographic and clinicopathologic factors, and survival information were extracted and tested using chi 2 and Kapl...
متن کاملEvaluation and outcomes of pediatric pleural effusions in over 10 years in Northwest, Iran
Abstract Background: Pleural effusion is the accumulation of excess fluid in the pleural cavity. Most information available about pleural effusion is obtained from studies on adults and little evidence is available in children. Therefore, it is necessary to identify the existing status and explain the disease process, signs, treatment, and prognosis. Children with pleural effusion who were admi...
متن کاملBeneficial Effects of Combining Nilotinib and Imatinib in Preclinical Models of BCR/ABL+ Leukemias Nilotinib and Imatinib Against Bcr-Abl+ Leukemia
Grant Support: J.D.G is supported by NIH grant CA66996, and a Specialized Center of Research Award from the Leukemia and Lymphoma Society. J.D.G. is also supported by NIH grants CA36167 and DK50654. P.W.M., J.M., and D.F. are employees of Novartis Pharma AG, Basel, Switzerland. J.D.G. has a financial interest with Novartis Pharma AG. Blood First Edition Paper, prepublished online October 26, 20...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Pharmaceutical Care
سال: 2021
ISSN: 2322-4509,2322-4630
DOI: 10.18502/jpc.v8i4.5238